Paper Details

  1. Home
  2. Paper Details

Angiographic Cystoid Macular Edema and Outcomes in the Comparison of Age-Related Macular Degeneration Treatments Trials.

Author: , DanielEbenezer, GrunwaldJuan E, JaffeGlenn J, MaguireMaureen G, MartinDaniel F, ShafferJames, ShahNeepa, TothCynthia A, YingGui-Shuang

Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Eyes with CME had worse baseline and follow-up VA, although all groups showed similar rates of improvement in VA during 2 years of follow-up. Cystoid macular edema seems to be a marker for poorer visual outcomes in nAMD because of underlying baseline retinal dysfunction and subsequent scarring. At baseline, eyes with CME had worse mean VA (letters) than eyes with IRF without CME and eyes with neither CME nor IRF (52 vs. 60 vs. 66 letters, P < 0.001).
Paper Details　
Original Abstract of the Article :
PURPOSE: To describe morphologic and visual outcomes in eyes with angiographic cystoid macular edema (CME) treated with ranibizumab or bevacizumab for neovascular age-related macular degeneration (nAMD). DESIGN: Prospective cohort study within a randomized clinical trial. PARTICIPANTS: A total of ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/26778329

データ提供：米国国立医学図書館（NLM）

Cystoid Macular Edema: A Marker for Poorer Visual Outcomes in Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults. Cystoid macular edema (CME) is a common complication of neovascular AMD that can significantly impact visual acuity. This study examines the relationship between CME and visual outcomes in patients with neovascular AMD who were treated with ranibizumab or bevacizumab.

CME: A Predictor of Poorer Visual Outcomes in Neovascular AMD

The study found that eyes with CME at baseline had worse visual acuity compared to those without CME. While both groups showed improvement in vision over time, the group with CME started and ended with worse visual acuity. The study also noted that eyes with CME had a higher rate of scarring, suggesting that CME may be a marker for poorer visual outcomes in neovascular AMD.

Navigating the Desert of AMD: Understanding the Impact of CME

This research provides valuable insights into the impact of CME on visual outcomes in neovascular AMD. Understanding the association between CME and poorer visual acuity can help guide treatment strategies and potentially improve patient outcomes. Early detection and management of CME may be crucial in preserving vision and mitigating the long-term effects of this complication.

Dr.Camel's Conclusion

The desert of AMD can be a challenging landscape, but understanding the nuances of this disease is crucial for effective treatment. This research highlights the significance of CME in predicting poorer visual outcomes in neovascular AMD. By recognizing the impact of CME, we can work towards more personalized and targeted treatment approaches, aiming to preserve vision and improve the quality of life for those affected by AMD.

Date :
  1. Date Completed 2016-08-11
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26778329

DOI: Digital Object Identifier

NIHMS743868

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.